Ginkgo Bioworks (DNA) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed Valneva (VALN) over the past year, losing 8.7% versus a loss of 40.1%. Over five years, VALN leads with a -91.3% price change compared with -98.5% for DNA. Valneva is the larger company by market cap ($490.9 million vs $483.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | VALN |
|---|---|---|
| Share price | $7.46 | $5.16 |
| Market cap | $483.54M | $490.86M |
| 1-day change | -9.02% | -3.82% |
| YTD return | -10.23% | -41.50% |
| 1-year return | -8.69% | -40.14% |
| 5-year return | -98.45% | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-4.24 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.16M | — |
| Revenue growth (YoY) | -25.06% | — |
| Net income (latest FY) | $-312.76M | — |
| Operating margin | -185.29% | — |
| Net margin | -183.81% | — |
| 52-week high | $18.22 | $12.18 |
| 52-week low | $5.37 | $4.75 |
| Distance from 52-week high | -59.06% | -57.64% |
| Analyst consensus | underperform | none |
| Avg. price target upside | +7.24% | +137.98% |
| Average volume | 2.53M | 23.10K |
| Shares outstanding | 53.94M | 95.13M |
| Employees | 485 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNA has outperformed VALN by 31.4 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
DNA vs VALN FAQ
Which is bigger, Ginkgo Bioworks or Valneva?
Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $483.54M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or VALN?
DNA returned -8.69% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.